Free Trial
NASDAQ:UPB

Upstream Bio (UPB) Stock Price, News & Analysis

Upstream Bio logo
$18.35 +2.05 (+12.58%)
As of 01/3/2025 05:39 PM Eastern

About Upstream Bio Stock (NASDAQ:UPB)

Key Stats

Today's Range
$16.05
$18.72
50-Day Range
$16.11
$27.39
52-Week Range
$14.97
$29.46
Volume
270,816 shs
Average Volume
221,158 shs
Market Capitalization
$983.50 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$56.50
Consensus Rating
Buy

Company Overview

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.

Upstream Bio Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
38th Percentile Overall Score

UPB MarketRank™: 

Upstream Bio scored higher than 38% of companies evaluated by MarketBeat, and ranked 750th out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Upstream Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Upstream Bio has only been the subject of 4 research reports in the past 90 days.

  • Read more about Upstream Bio's stock forecast and price target.
  • Earnings Growth

    Earnings for Upstream Bio are expected to grow in the coming year, from ($4.30) to ($2.37) per share.

  • Short Interest

    There is no current short interest data available for UPB.
  • Dividend Yield

    Upstream Bio does not currently pay a dividend.

  • Dividend Growth

    Upstream Bio does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for UPB.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Upstream Bio this week, compared to 2 articles on an average week.
  • Search Interest

    1 people have searched for UPB on MarketBeat in the last 30 days.
  • MarketBeat Follows

    2 people have added Upstream Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Upstream Bio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $34,000,000.00 in company stock and sold $0.00 in company stock.

  • Read more about Upstream Bio's insider trading history.
Receive UPB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Upstream Bio and its competitors with MarketBeat's FREE daily newsletter.

UPB Stock News Headlines

Upstream Bio (NASDAQ:UPB) Stock Price Down 3% - Here's Why
Upstream Bio Appoints Allison Ambrose as General Counsel
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.
Upstream Bio to join Russell 2000 index
Upstream Bio Announces Addition to Russell 2000® Index
See More Headlines

UPB Stock Analysis - Frequently Asked Questions

Upstream Bio's stock was trading at $16.44 at the start of the year. Since then, UPB stock has increased by 11.6% and is now trading at $18.35.
View the best growth stocks for 2025 here
.

Upstream Bio, Inc. (NASDAQ:UPB) released its quarterly earnings results on Thursday, November, 7th. The company reported ($6.96) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.58) by $6.38. The business earned $0.61 million during the quarter, compared to analysts' expectations of $0.83 million.

Upstream Bio (UPB) raised $200 million in an initial public offering (IPO) on Friday, October 11th 2024. The company issued 12,500,000 shares at a price of $15.00-$17.00 per share. JPMorgan, TD Cowen, Piper Sandler and William Blair acted as the underwriters for the IPO.

Upstream Bio's quiet period expired on Wednesday, November 20th. Upstream Bio had issued 15,000,000 shares in its initial public offering on October 11th. The total size of the offering was $255,000,000 based on an initial share price of $17.00. During the company's quiet period, insiders and any underwriters involved in the IPO were prevented from issuing any research reports or earnings estimates for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.

Shares of UPB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

Last Earnings
11/07/2024
Today
1/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:UPB
Previous Symbol
NASDAQ:UPB
Fax
N/A
Employees
38
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$56.50
High Stock Price Target
$75.00
Low Stock Price Target
$38.00
Potential Upside/Downside
+207.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$2.21 million

Miscellaneous

Free Float
N/A
Market Cap
$983.50 million
Optionable
N/A
Beta
N/A
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

This page (NASDAQ:UPB) was last updated on 1/5/2025 by MarketBeat.com Staff
From Our Partners